Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rich-Vicks' ibuprofen/pseudoephedrine "synergy" claim "irrelevant" to patent suit -- McNeil.

This article was originally published in The Tan Sheet

Executive Summary

RICH-VICKS' IBUPROFEN/PSEUDOEPHEDRINE "SYNERGY" CLAIM "IRRELEVANT," McNEIL maintained in a brief filed with the U.S. Court of Appeals for the Federal Circuit on May 22. The document responds to Richardson-Vicks' appeal of a Jan. 17 district court decision that the Procter & Gamble unit's patent for 200 mg ibuprofen/30 mg pseudoephedrine in cough/cold products was not valid and enforceable because the combination was obvious to anyone with medical experience in the OTC cough/cold industry ("The Tan Sheet" Jan. 22, p. 1).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085520

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel